Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-011299
Filing Date
2025-08-13
Accepted
2025-08-13 07:10:29
Documents
73
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q pmn-20250630x10q.htm   iXBRL 10-Q 1629258
2 EX-10.1 pmn-20250630xex10d1.htm EX-10.1 337387
3 EX-31.1 pmn-20250630xex31d1.htm EX-31.1 8943
4 EX-31.2 pmn-20250630xex31d2.htm EX-31.2 8833
5 EX-32.1 pmn-20250630xex32d1.htm EX-32.1 10719
  Complete submission text file 0001558370-25-011299.txt   7154388

Data Files

Seq Description Document Type Size
6 EX-101.SCH pmn-20250630.xsd EX-101.SCH 51152
7 EX-101.CAL pmn-20250630_cal.xml EX-101.CAL 33198
8 EX-101.DEF pmn-20250630_def.xml EX-101.DEF 169091
9 EX-101.LAB pmn-20250630_lab.xml EX-101.LAB 392723
10 EX-101.PRE pmn-20250630_pre.xml EX-101.PRE 301132
76 EXTRACTED XBRL INSTANCE DOCUMENT pmn-20250630x10q_htm.xml XML 1234930
Mailing Address SUITE 200, 1920 YONGE STREET TORONTO A6 M4S 3E2
Business Address SUITE 200, 1920 YONGE STREET TORONTO A6 M4S 3E2 416-847-6898
ProMIS Neurosciences Inc. (Filer) CIK: 0001374339 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41429 | Film No.: 251208971
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)